{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:58:15Z","timestamp":1772830695329,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Aromatic <jats:sc>l<\/jats:sc>-amino acid decarboxylase (AADC) deficiency is a rare genetic disorder with heterogeneous phenotypic spectrum resulting from disease-causing variants in the dopa decarboxylase (<jats:italic>DDC<\/jats:italic>) gene. Consensus guidelines recommend dopamine agonists, monoamine oxidase inhibitors, and other symptomatic treatments, but most patients have an unrelenting disease course with no response to these therapies.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We describe 2 African American siblings with AADC deficiency and identify 2 <jats:italic>DDC<\/jats:italic> gene variants not previously associated with the disorder. The patients were evaluated for cognitive and neurologic impairments. Diagnosis of AADC deficiency was initially based on evaluation of urine and plasma metabolites, followed by targeted <jats:italic>DDC<\/jats:italic> gene sequencing. The first patient, a firstborn African American female, had moderate elevations of vanillactic and vanilpyruvic acids, and slight elevation of N-acetylvanilalanine in urine. The second patient, an African American female and younger sibling of the first patient, had low AADC enzyme activity and elevated 3-<jats:italic>O<\/jats:italic>-methyldopa levels in plasma. Genetic testing confirmed that both siblings possessed the same 2 <jats:italic>DDC<\/jats:italic> gene variants, which were identified as NM_000790.3: c.48C\u2009&gt;\u2009A (p.Tyr16Ter) and NM_000790.3: c.116G\u2009&gt;\u2009C (p.Arg39Pro).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This report describes 2 previously unknown patients with AADC deficiency and confirmed the presence of 2 <jats:italic>DDC<\/jats:italic> gene variants not previously associated with this disorder. Further research is needed to identify disease-modifying treatments for this devastating neurometabolic disorder. Gene therapy with a recombinant adeno-associated viral vector serotype 2 carrying the gene for the human AADC protein (AAV2-hAADC) is currently in clinical development.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-019-1596-8","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T16:02:27Z","timestamp":1578585747000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Case report: discovery of 2 gene variants for aromatic L-amino acid decarboxylase deficiency in 2 African American siblings"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-4995","authenticated-orcid":false,"given":"Berrin","family":"Monteleone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"issue":"2\u20133","key":"1596_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ymgme.2015.04.008","volume":"115","author":"PS Atwal","year":"2015","unstructured":"Atwal PS, Donti TR, Cardon AL, Bacino CA, Sun Q, Emrick L, Reid Sutton V, Elsea SH. Aromatic L-amino acid decarboxylase deficiency diagnosed by clinical metabolomic profiling of plasma. Mol Genet Metab. 2015;115(2\u20133):91\u20134.","journal-title":"Mol Genet Metab"},{"key":"1596_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/8904_2014_327","volume":"17","author":"G Helman","year":"2014","unstructured":"Helman G, Pappa MB, Pearl PL. Widening phenotypic spectrum of AADC deficiency, a disorder of dopamine and serotonin synthesis. JIMD Rep. 2014;17:23\u20137.","journal-title":"JIMD Rep"},{"issue":"1","key":"1596_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13023-016-0522-z","volume":"12","author":"T Wassenberg","year":"2017","unstructured":"Wassenberg T, Molero-Luis M, Jeltsch K, Hoffmann GF, Assmann B, Blau N, Garcia-Cazorla A, Artuch R, Pons R, Pearson TS, et al. Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. Orphanet J Rare Dis. 2017;12(1):12.","journal-title":"Orphanet J Rare Dis"},{"key":"1596_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgmr.2016.09.006","volume":"9","author":"T Opladen","year":"2016","unstructured":"Opladen T, Cortes-Saladelafont E, Mastrangelo M, Horvath G, Pons R, Lopez-Laso E, Fernandez-Ramos JA, Honzik T, Pearson T, Friedman J, et al. The international working group on neurotransmitter related disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders. Mol Genet Metab Rep. 2016;9:61\u20136.","journal-title":"Mol Genet Metab Rep"},{"issue":"8","key":"1596_CR5","doi-asserted-by":"publisher","first-page":"e71741","DOI":"10.1371\/journal.pone.0071741","volume":"8","author":"DF Shih","year":"2013","unstructured":"Shih DF, Hsiao CD, Min MY, Lai WS, Yang CW, Lee WT, Lee SJ. Aromatic L-amino acid decarboxylase (AADC) is crucial for brain development and motor functions. PLoS One. 2013;8(8):e71741.","journal-title":"PLoS One"},{"issue":"4","key":"1596_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2016.05.011","volume":"118","author":"YH Chien","year":"2016","unstructured":"Chien YH, Chen PW, Lee NC, Hsieh WS, Chiu PC, Hwu WL, Tsai FJ, Lin SP, Chu SY, Jong YJ, et al. 3-O-methyldopa levels in newborns: result of newborn screening for aromatic l-amino-acid decarboxylase deficiency. Mol Genet Metab. 2016;118(4):259\u201363.","journal-title":"Mol Genet Metab"},{"key":"1596_CR7","unstructured":"Whitehead N, Schu M, Erickson SW, Croxford J, Peters M, Hyland K. Estimated prevalence of aromatic L-amino acid decarboxylase (AADC) deficiency in the United States, European Union, and Japan [poster]. In: Presented at: Annual Congress of the European Society for Gene and Cell Therapy: October 16-19, 2018; Lausanne."},{"key":"1596_CR8","unstructured":"Hyland K, Reott M: Prevalence of aromatic L-amino acid decarboxylase deficiency in at-risk population [poster]. In: Presented at: Annual Meeting of the American Society of Gene and Cell Therapy: May 16-19, 2018; Chicago."},{"issue":"Suppl 6","key":"1596_CR9","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1002\/ana.10631","volume":"54","author":"KJ Swoboda","year":"2003","unstructured":"Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol. 2003;54(Suppl 6):S49\u201355.","journal-title":"Ann Neurol"},{"issue":"1","key":"1596_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1212\/WNL.0b013e3181e620ae","volume":"75","author":"L Brun","year":"2010","unstructured":"Brun L, Ngu LH, Keng WT, Ch'ng GS, Choy YS, Hwu WL, Lee WT, Willemsen MA, Verbeek MM, Wassenberg T, et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology. 2010;75(1):64\u201371.","journal-title":"Neurology"},{"key":"1596_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2014.01.034","volume":"431","author":"PW Chen","year":"2014","unstructured":"Chen PW, Lee NC, Chien YH, Wu JY, Wang PC, Hwu WL. Diagnosis of aromatic L-amino acid decarboxylase deficiency by measuring 3-O-methyldopa concentrations in dried blood spots. Clin Chim Acta. 2014;431:19\u201322.","journal-title":"Clin Chim Acta"},{"issue":"4 Movement Diso","key":"1596_CR12","first-page":"1159","volume":"22","author":"MA Kurian","year":"2016","unstructured":"Kurian MA, Dale RC. Movement disorders presenting in childhood. Continuum (Minneapolis, Minn). 2016;22(4 Movement Disorders):1159\u201385.","journal-title":"Continuum (Minneapolis, Minn)"},{"issue":"1","key":"1596_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10545-017-0079-6","volume":"41","author":"A Kuster","year":"2018","unstructured":"Kuster A, Arnoux JB, Barth M, Lamireau D, Houcinat N, Goizet C, Doray B, Gobin S, Schiff M, Cano A, et al. Diagnostic approach to neurotransmitter monoamine disorders: experience from clinical, biochemical, and genetic profiles. J Inherit Metab Dis. 2018;41(1):129\u201339.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"1596_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1177\/0883073807302619","volume":"22","author":"PL Pearl","year":"2007","unstructured":"Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol. 2007;22(5):606\u201316.","journal-title":"J Child Neurol"},{"issue":"7","key":"1596_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1212\/WNL.62.7.1058","volume":"62","author":"R Pons","year":"2004","unstructured":"Pons R, Ford B, Chiriboga CA, Clayton PT, Hinton V, Hyland K, Sharma R, De Vivo DC. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology. 2004;62(7):1058\u201365.","journal-title":"Neurology"},{"issue":"11","key":"1596_CR16","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1210\/jc.2013-2740","volume":"98","author":"JB Arnoux","year":"2013","unstructured":"Arnoux JB, Damaj L, Napuri S, Serre V, Hubert L, Cadoudal M, Simard G, Ceballos I, Christa L, de Lonlay P. Aromatic L-amino acid decarboxylase deficiency is a cause of long-fasting hypoglycemia. J Clin Endocrinol Metab. 2013;98(11):4279\u201384.","journal-title":"J Clin Endocrinol Metab"},{"key":"1596_CR17","unstructured":"AADC deficiency is a rare, devastating disorder of the central nervous system. Available at: [https:\/\/aadcinsights.com\/about\/]. Accessed 6 Jan 2020."},{"issue":"12","key":"1596_CR18","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/clinchem\/38.12.2405","volume":"38","author":"K Hyland","year":"1992","unstructured":"Hyland K, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992;38(12):2405\u201310.","journal-title":"Clin Chem"},{"issue":"1","key":"1596_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymgme.2019.03.009","volume":"127","author":"Nastassja Himmelreich","year":"2019","unstructured":"Himmelreich N, Montioli R, Bertoldi M, Carducci C, Leuzzi V, Gemperle C, Berner T, Hyland K, Thony B, Hoffmann GF, et al. Aromatic amino acid decarboxylase deficiency: molecular and metabolic basis and therapeutic outlook. Mol Genet Metab. 2019;127(1):12\u201322.","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"1596_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ymgme.2005.09.007","volume":"87","author":"JE Abdenur","year":"2006","unstructured":"Abdenur JE, Abeling N, Specola N, Jorge L, Schenone AB, van Cruchten AC, Chamoles NA. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006;87(1):48\u201353.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"1596_CR21","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2352-4642(17)30125-6","volume":"1","author":"YH Chien","year":"2017","unstructured":"Chien YH, Lee NC, Tseng SH, Tai CH, Muramatsu S, Byrne BJ, Hwu WL. Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1\/2 trial. Lancet Child Adolesc Health. 2017;1(4):265\u201373.","journal-title":"Lancet Child Adolesc Health"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1596-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1596-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:30:53Z","timestamp":1610065853000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1596-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1596"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1596-8","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"20 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable; no patient-specific identifier or personal information is presented in this report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parents of all individual participants included in the case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Berrin Monteleone, MD: Consultant to Agilis Biotherapeutics\/PTC Therapeutics, GTC, Inc.Keith Hyland, PhD: Consultant for Censa Pharmaceuticals and Agilis Biotherapeutics\/PTC Therapeutics, GTC, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}